Wiser Optomed Wins Third Prize in AI+Eye Health Track at Inaugural Global Technology Innovation Competition

Guangdong, China – December 16, 2025 – Wiser Optomed Medical Technologies (“Wiser Optomed”), a joint venture between Wiser and Optomed, announced today that its AI-powered retinal screening solution has been awarded Third Prize in the AI+Eye Health track at the inaugural Global Technology Innovation Competition.

Hosted under the theme “Global Innovation, Empowerment in Zhejiang,” the competition focused on four cutting-edge sectors: humanoid robotics, biotech, AI+eye health, and aerospace. It invited innovative, commercially viable projects from global universities, research institutions, and startups under five years old.

Launched in July 2025, the competition attracted over 640 high-quality entries from more than 10 countries and regions worldwide. After six months of rigorous evaluation, 29 projects were selected as winners, including 4 first prizes, 8 second prizes, and 17 third prizes. China Eye Valley led a cohort of global startups to secure 1 first, 2 second, and 7 third prizes in the AI+Eye Health track, with Wiser Optomed’s solution recognized among the top honorees.

The winning projects addressed urgent clinical needs through advanced technologies such as artificial intelligence (AI), augmented reality (AR), and precision metrology. A key theme across entries was improving healthcare accessibility and affordability, with portable, intelligent screening tools designed to bring high-quality care to grassroots communities and households—addressing global disparities in healthcare resource distribution.

Wiser Optomed’s integrated solution combines a portable handheld fundus camera, AI-assisted diagnostics, and Huawei Cloud-based screening management platform, specifically engineered for primary care settings.

Headquartered in the Greater Bay Area, Wiser Optomed has integrated the world’s first handheld fundus camera certified by NMPA, FDA, and CE with local AI algorithms. Co-developed with top global ophthalmologists, its screening system targets four major retinal conditions: diabetic retinopathy, glaucoma, macular degeneration, and cataracts. Deployed locally on Huawei Cloud, the platform delivers hospital-grade chronic eye disease screening and health management services to community hospitals, clinics, pharmacies, and optical centers.

Wiser Optomed is committed to leveraging AI to accelerate early detection of chronic diseases at the grassroots level, driving China’s primary healthcare transformation from a “treatment-centered” model to a “people’s health-centered” system.